EU: European Union and Commission launch EU4Health funding program to boost healthcare digitalization and make devices more accessible
As COVID-19 keeps surging throughout many of the European countries, the EU and EU Commission launched EU4Health, the €5.1 billion funding program targeting EU countries, health organisations and NGOs. Aim of the program is to strengthen the resilience of post COVID19 healthsystems and to promote innovation in the health sector.
The program will cover the following areas:
- boost EU’s preparedness for major cross border health threats by creating
- reserves of medical supplies for crises
- a reserve of healthcare staff and experts that can be mobilised to respond to crises across the EU
- increased surveillance of health threats
- strengthen health systems so that they can face epidemics as well as long-term challenges by stimulating
- disease prevention and health promotion in an ageing population
- digital transformation of health systems
- access to health care for vulnerable groups
- make medicines and medical devices available and affordable, advocate the prudent and efficient use of antimicrobials as well as promote medical and pharmaceutical innovation and greener manufacturing.
For more details on regulations and application, please visit the official communication from the European Commission.
Contact Meditrial for immediate assistance in Europe or the US.
Table of Contents
Build a Defensible Clinical Evidence Strategy Under EU MDR
Build a defensible clinical evidence strategy under MDR Annex XIV, from the clinical evaluation plan to PMCF and notified body review.
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
A Practical RBQM Framework for Medical Device Trials
Risk-based quality management for medical device trials, with practical actions for risk assessment, monitoring, data review, and trial oversight
EU Breakthrough Medical Devices Under MDCG 2025-9 (BtX)
EU breakthrough medical devices gain a clearer regulatory pathway under MDCG 2025-9, with early advice and lifecycle evidence planning
What Swissmedic Fast-Track Means for Clinical Trial Sponsors
Swissmedic swissethics Fast-Track Pilot Project accelerates eligible trial reviews and makes coordinated regulatory preparation increasingly important.
FDA Breakthrough Device Acceleration
How innovative MedTech companies can accelerate FDA approval, secure Medicare coverage, and reach patients faster—starting with Breakthrough Device Designation.
This article provides general information and does not constitute regulatory or legal advice. Requirements should be confirmed for the specific study, applicable regulatory framework, and markets concerned.
